Drug Trial Radar · NCT00930553
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Last checked: Nov 20, 2026Latest source record: May 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,314
Actual
Start
Aug 2009
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Jun 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223 \[NCT00050778\], CAMMS323 \[NCT00530348\] also known as CARE-MS I, or CAMMS324 \[NCT00548405\] also known as CARE-MS II). The purposes of this study were: 1. To examine the long term safety and efficacy of alemtuzumab treatment in participants who received alemtuzumab as their study treatment in one of the prior studies. 2. To examine the safety and efficacy of initial alemtuzumab treatment in this study for participants who received Rebif® (interferon beta-1a) as their study treatment in one of the prior studies. 3. To determine the safety and efficacy of additional "as needed" alemtuzumab treatment courses. This applied both to participants who received alemtuzumab for the first time in one of the prior studies or for the first time in this extension study.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumabBiological
Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)
- Annualized Relapse Rate (ARR) Before and After Receiving AlemtuzumabTime frame: Baseline (Year 0 of initial studies) up to Year 4
- Annualized Relapse Rate (ARR) Before and After Alemtuzumab RetreatmentTime frame: Year 1 prior to retreatment, Year 1, 2, 3 after retreatment
- Number of Participants With Sustained Accumulation of Disability (SAD)Time frame: Baseline (Year 0) up to Year 6
- Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year ComparisonTime frame: Baseline (Year 0 of initial studies) up to Year 4
Locations
176 sites in 23 countries. Site status is shown where the registry gives one.
North Central Neurology Associates, P.C.
Cullman, Alabama
HOPE Research Institute
Phoenix, Arizona
St. Joseph's Hospital and Medical Center Barrow Neurology Clinics - Barrow Neurological Institute
Phoenix, Arizona
Mayo Clinic Arizona (Scottsdale)
Scottsdale, Arizona
Northwest NeuroSpecialists, PLLC
Tucson, Arizona
East Bay Physicians Medical Group/ Sutter East Bay Medical Foundation
Berkeley, California
Neurology Center North Orange County
La Habra, California
University of Southern California Keck School of Medicine/University of Southern California LAC & USC Medical Center
Los Angeles, California
Neuro-Therapeutics, Inc.
Pasadena, California
Stanford University Medical Center
Stanford, California
University of Colorado Health Science Center - Aurora
Aurora, Colorado
Advanced Neurology of Colorado
Fort Collins, Colorado
Yale MS Research Center
New Haven, Connecticut
The George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
University of Florida Neuroscience Institute
Jacksonville, Florida
Neurology Associates, P.A.
Maitland, Florida
Neurological Associates
Pompano Beach, Florida
Negroski, Stein, Sutherland and Hanes Neurology
Sarasota, Florida
Axiom Clinical Research of Florida
Tampa, Florida
University of South Florida College of Medicine
Tampa, Florida
Emory University Department of Neurology
Atlanta, Georgia
Shepherd Center Multiple Sclerosis Institute
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Consultants in Neurology, LTD
Northbrook, Illinois
Fort Wayne Neurological Center
Fort Wayne, Indiana
Indiana University Multiple Sclerosis Center
Indianapolis, Indiana
Iowa Health Physicians
Des Moines, Iowa
Ruan Neurology Clinic and Clinical Research Center, Mercy Medical Center
Des Moines, Iowa
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas
MidAmerica Neuroscience Institute
Lenexa, Kansas
Associates in Neurology, P.S.C.
Lexington, Kentucky
Kentucky Neuroscience Research
Louisville, Kentucky
University of Maryland, Maryland Center for MS
Baltimore, Maryland
The MS Center at St. Elizabeth's
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
University of Michigan Medical School
Ann Arbor, Michigan
Michigan Neurology Association
Clinton, Michigan
Wayne State University, The School of Medicine, Department of Neurology
Detroit, Michigan
Spectrum Health Medical Group, Neurology/Michigan Medical P.C., West Michigan MS Clinic
Grand Rapids, Michigan
Northern Michigan Neurology
Traverse City, Michigan
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.